Bambusa Initiates Subcutaneous BBT001 Dosing in Atopic Dermatitis
Bambusa Therapeutics has initiated subcutaneous dosing of BBT001 in atopic dermatitis, transitioning from an intravenous proof-of-concept phase the sponsor called 'compelling.'
Topic
Drug Development
Topic
Drug Development
Selective Oral JAK/TEK Inhibitor Succeeds in Phase 3 Vitiligo Trial
A selective oral JAK/TEK inhibitor proved effective in a Phase 3 vitiligo trial, advancing targeted systemic therapy for a diseas…
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
Dermatology Times' Q3 2026 review rounds up FDA approvals and clinical readouts in dermatology; the syndicated headline did not i…
MYC Emerges as a Key Therapeutic Target in Melanoma
A new Frontiers review positions the transcription factor MYC as a convergent, functionally critical target in melanoma, surveyin…
Regeneron Shares Fall as Skin Cancer Therapy Misses in Late-Stage Trial
Regeneron shares dropped after a skin cancer treatment failed a late-stage trial. Details on the drug, indication and endpoint pe…